– USA, MA – KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced the appointment of Dr. Laurence Reid (Ph.D) to its Board of Directors, effective immediately, bringing more than three decades of experience with a track record of leadership and company-building success.
“I am pleased to welcome Dr. Reid, with his deep expertise in high-growth biotech companies, to the KalVista Board of Directors,” said CEO, Ben Palleiko. “His extensive biopharmaceutical and strategic experience will be a tremendous asset as the Company continues to progress sebetralstat towards global market approval and commercialization.”
About Dr. Laurence Reid
Dr. Laurence Reid was the CEO of Decibel Therapeutics before its acquisition by Regeneron Pharmaceuticals in September 2023. Previously, Dr. Reid served as an entrepreneur in residence at Third Rock Ventures, where he focused on novel drug discovery opportunities. Before Third Rock, he was CEO of Warp Drive Bio, a small molecule company focused on novel oncology and antibiotic drug discovery based on natural products, until its merger with Revolution Medicines in 2018. He also served as CBO of Alnylam Pharmaceuticals and Ensemble Therapeutics and held senior leadership roles at Millennium Pharmaceuticals. Dr. Reid currently serves as the chair of the board of Broken String Biosciences, is a board member of Garuda Therapeutics and The Possible Zone, and serves as a board advisor to Life Science Cares and Mount Auburn Hospital.
“I am excited to join the KalVista Board at this transformational time in the Company’s journey,” said Dr. Laurence Reid. “I believe sebetralstat has the potential to significantly improve the lives of people living with hereditary angioedema. I look forward to working with the team on the Company’s transition to a commercial organization and supporting its long-term growth.”
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a global pharmaceutical company whose mission is to develop and deliver life-changing oral medicines for people affected by rare diseases with significant unmet needs. Sebetralstat, our novel, investigational candidate for the oral, on-demand treatment of hereditary angioedema, is under regulatory review by the FDA with a PDUFA goal date of June 17, 2025. In addition, we have completed Marketing Authorization Application (MAA) submissions for sebetralstat to the European Medicines Agency and the United Kingdom, Switzerland, Australia, and Singapore.
For more: https://www.kalvista.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.